Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1489)	4/14/2004 9:39:15 AM
From: Biomaven	Read Replies (1) \| Respond to of 1826

March, 11, 2004 - Well I only got one taker for my Aloxi 2004 sales prediction contest - Ward, with a $150m prediction. To go with that, we have Merrill Lynch at $97.5m, which they say is street high, and mine at $140m. Message 19907920 From last month's release: March 17, 2004--MGI PHARMA, INC. (Nasdaq:MOGN - News) today announced that it expects sales of Aloxi(TM) injection for the first quarter of 2004 to exceed previous guidance of $12 million. MGI PHARMA now anticipates sales of Aloxi injection to be in the range of $15 million to $17 million for the first quarter. Recent trends indicate that 2004 annual sales of Aloxi injection could exceed prior guidance and range from $100 million to $110 million. From today's release: For the year ending December 31, 2004, we currently expect: -- Aloxi injection product sales to range from $115 million to $130 million One or two more upward adjustments and Ward's or my prediction will be well inside the ballpark. Peter